Paper Details

  1. Home
  2. Paper Details

Discovery of 2-Sulfinyl-Diazabicyclooctane Derivatives, Potential Oral β-Lactamase Inhibitors for Infections Caused by Serine β-Lactamase-Producing Enterobacterales.

Author: AokiToshiaki, FujiuMotohiro, HirakawaYuya, KanazawaSachi, KashiwagiEmi, KawachiTomoyuki, KohiraNaoki, KomanoKazuo, KusanoHiroki, MakiHideki, NagamatsuDaiki, SatoJun, SatoSoichiro, ShibuyaSatoru, WatariRyosuke, YamawakiKenji, YokooKatsuki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study discovered a novel diazabicyclooctane (DBO) β-lactamase inhibitor (BLI) that restores the antibacterial activity of ceftibuten against various serine β-lactamase-producing strains, including carbapenem-resistant Enterobacteriaceae (CRE). This BLI can be orally absorbed and exhibits in vivo efficacy in combination with ceftibuten.
Paper Details　
Original Abstract of the Article :
Coadministration of β-lactam and β-lactamase inhibitor (BLI) is one of the well-established therapeutic measures for bacterial infections caused by β-lactam-resistant Gram-negative bacteria, whereas we have only two options for orally active BLI, clavulanic acid and sulbactam. Further...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1021/acs.jmedchem.1c00799

データ提供：米国国立医学図書館（NLM）

Fighting Bacterial Resistance: A Race Against Time

In the relentless desert of antibiotic resistance, bacteria, like resilient nomads, continue to evolve, outsmarting our best defenses. This study, like a scientific expedition searching for new weapons, investigates the potential of 2-sulfinyl-diazabicyclooctane derivatives as oral β-lactamase inhibitors to combat infections caused by resistant bacteria.

New Weapons in the Arsenal: 2-Sulfinyl-Diazabicyclooctane Derivatives

The researchers, like skilled artisans, discovered a promising new compound, 2-sulfinyl-DBO derivative, that effectively inhibits β-lactamases, enzymes that break down β-lactam antibiotics, like a protective shield against a desert sandstorm. This finding, like a well-placed oasis, offers a potential solution to the growing problem of antibiotic resistance.

Hope on the Horizon: A Sustainable Future

This study, like a sustainable desert community, provides a glimmer of hope for the future of antibiotic treatment. The discovery of this new class of inhibitors could pave the way for the development of new and effective oral therapies against resistant bacteria. This research, like a well-charted route through the desert, could help us navigate the challenging landscape of antibiotic resistance and ensure that antibiotics remain effective weapons in the fight against bacterial infections.

Dr.Camel's Conclusion

This research, like a desert caravan carrying valuable supplies, brings new hope in the battle against bacterial resistance. The discovery of 2-sulfinyl-diazabicyclooctane derivatives as potential oral β-lactamase inhibitors, like a hidden oasis in the vast desert, offers a promising new avenue for tackling infections caused by resistant bacteria. As we continue to explore the ever-changing landscape of bacterial resistance, this research provides valuable insights and fuels our determination to find innovative solutions.
Date :
  1. Date Completed 2021-09-07
  2. Date Revised 2021-09-07
Further Info :

Pubmed ID

34143627

DOI: Digital Object Identifier

10.1021/acs.jmedchem.1c00799

Related Literature

Article Analysis
・Effects of ceftibuten
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.